RPG Life Sciences Limited

BSE:532983 Stock Report

Market Cap: ₹34.1b

RPG Life Sciences Valuation

Is 532983 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 532983 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 532983 (₹2058.4) is trading above our estimate of fair value (₹824.85)

Significantly Below Fair Value: 532983 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532983?

Key metric: As 532983 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 532983. This is calculated by dividing 532983's market cap by their current earnings.
What is 532983's PE Ratio?
PE Ratio48.2x
Earnings₹706.60m
Market Cap₹34.08b

Price to Earnings Ratio vs Peers

How does 532983's PE Ratio compare to its peers?

The above table shows the PE ratio for 532983 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average59.2x
506879 Gujarat Themis Biosyn
67.2xn/a₹35.4b
INDOCO Indoco Remedies
87.9x72.2%₹28.2b
500288 Morepen Laboratories
32.3xn/a₹42.3b
509079 Gufic Biosciences
49.5xn/a₹42.0b
532983 RPG Life Sciences
48.2xn/a₹34.1b

Price-To-Earnings vs Peers: 532983 is good value based on its Price-To-Earnings Ratio (48.2x) compared to the peer average (59.2x).

Price to Earnings Ratio vs Industry

How does 532983's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.5xn/aUS$66.29m
524652 Ind-Swift
2.1xn/aUS$13.37m
No more companies available in this PE range
532983 48.2xIndustry Avg. 34.2xNo. of Companies17PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 532983 is expensive based on its Price-To-Earnings Ratio (48.2x) compared to the Indian Pharmaceuticals industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is 532983's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532983 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio48.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 532983's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Novartis India

₹26.0b

Operates as a healthcare company in India.

500672

₹1,053.70

7D

3.0%

1Y

50.6%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

7D

0.8%

1Y

-23.0%